TY - JOUR
T1 - Targeting B cells and plasma cells in autoimmune diseases
T2 - From established treatments to novel therapeutic approaches
AU - Merino-Vico, Ana
AU - Frazzei, Giulia
AU - van Hamburg, Jan Piet
AU - Tas, Sander W.
N1 - Funding Information: We obtained grant support from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847551 (A.M.-V., G.F.). Funding Information: We obtained grant support from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie grant agreement no. 847551 (A.M.‐V., G.F.). Publisher Copyright: © 2022 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
PY - 2023/1
Y1 - 2023/1
N2 - Autoimmune diseases are characterized by the recognition of self-antigens by the immune system, which leads to inflammation and tissue damage. B cells are directly and indirectly involved in the pathophysiology of autoimmunity, both via antigen-presentation to T cells and production of proinflammatory cytokines and/or autoantibodies. Consequently, B lineage cells have been identified as therapeutic targets in autoimmune diseases. B cell depleting strategies have proven beneficial in the treatment of rheumatoid arthritis (RA), systemic lupus erythematous (SLE), ANCA-associated vasculitis (AAV), multiple sclerosis (MS), and a wide range of other immune-mediated inflammatory diseases (IMIDs). However, not all patients respond to treatment or may not reach (drug-free) remission. Moreover, B cell depleting therapies do not always target all B cell subsets, such as short-lived and long-lived plasma cells. These cells play an active role in autoimmunity and in certain diseases their depletion would be beneficial to achieve disease remission. In the current review article, we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with the focus on rheumatic diseases. Both advanced therapies that have recently become available and more experimental treatments that may reach the clinic in the near future are discussed.
AB - Autoimmune diseases are characterized by the recognition of self-antigens by the immune system, which leads to inflammation and tissue damage. B cells are directly and indirectly involved in the pathophysiology of autoimmunity, both via antigen-presentation to T cells and production of proinflammatory cytokines and/or autoantibodies. Consequently, B lineage cells have been identified as therapeutic targets in autoimmune diseases. B cell depleting strategies have proven beneficial in the treatment of rheumatoid arthritis (RA), systemic lupus erythematous (SLE), ANCA-associated vasculitis (AAV), multiple sclerosis (MS), and a wide range of other immune-mediated inflammatory diseases (IMIDs). However, not all patients respond to treatment or may not reach (drug-free) remission. Moreover, B cell depleting therapies do not always target all B cell subsets, such as short-lived and long-lived plasma cells. These cells play an active role in autoimmunity and in certain diseases their depletion would be beneficial to achieve disease remission. In the current review article, we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with the focus on rheumatic diseases. Both advanced therapies that have recently become available and more experimental treatments that may reach the clinic in the near future are discussed.
KW - B cells
KW - autoantibodies
KW - autoimmune diseases
KW - plasma cells
KW - rheumatic diseases
UR - http://www.scopus.com/inward/record.url?scp=85142287084&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/eji.202149675
DO - https://doi.org/10.1002/eji.202149675
M3 - Article
C2 - 36314264
SN - 0014-2980
VL - 53
JO - European journal of immunology
JF - European journal of immunology
IS - 1
M1 - 2149675
ER -